Program
benralizumab
Also written as “Benralizumab”, “Benralizumab 100 mg” and “KHK4563”.
Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Churg-Strauss Syndrome · Nasal Polyps · Hypereosinophilic Syndrome, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 465 open or running | phase 4since Apr 10, 2019 | Aug 6, 2007 | Dec 23, 2026phase 3 · NCT05692180 |
| Kyowa Kirin | 20 open or running | phase 2since Aug 7, 2011 | Aug 7, 2011 | none ahead |
Also a collaborator on its studies: parexel, iqvia-pty-ltd, covance and ppd-development-lp.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 32 studies since Aug 6, 2007.
- Oct 23, 2019Phase 3 study in Nasal PolypsAstraZeneca · NCT04157335 · 295 enrolled · United States, Argentina, Australia and more
- Nov 15, 20192 phase 3 studiesAstraZeneca · NCT04305405, NCT04191304
- Aug 18, 2020Phase 3 study in Eosinophilic EsophagitisAstraZeneca · NCT04543409 · 211 enrolled · United States, Canada, France and more
- Sep 1, 20202 phase 2 studiesAstraZeneca · NCT04605094, NCT04612725
- Oct 12, 2020Phase 3 study in Pemphigoid, BullousAstraZeneca · NCT04612790 · 67 enrolled · United States, Australia, Bulgaria and more
- Jun 23, 2021Phase 3 study in Non-cystic Fibrosis BronchiectasisAstraZeneca · NCT05006573 · 100 enrolled · United States, Argentina, Australia and more
- Aug 6, 2021Phase 3 study in Eosinophilic enteropathyAstraZeneca · NCT05251909 · 12 enrolled · United States, Brazil, Italy and more
- Nov 9, 2021Phase 4 study in In Adult Patients of Severe Asthma With Eosinophilic Phenotype in IndiaAstraZeneca · NCT05384938 · 139 enrolled · India
- Apr 27, 2022Phase 4 study in AsthmaAstraZeneca · NCT05552508 · 45 enrolled · United States, Australia, Belgium and more
- Jan 11, 2023Phase 3 study in AsthmaAstraZeneca · NCT05692180 · 94 enrolled · United States, Argentina, France and more
- Feb 1, 2024Phase 3 study in Pulmonary EosinophiliaAstraZeneca · NCT06465485 · 504 enrolled · China
- Jul 17, 2024Phase 3 study in Churg-Strauss SyndromeAstraZeneca · NCT06512883 · 14 planned · United States, Brazil, Canada and more
- Nov 20, 2024Phase 3 study in Pulmonary EosinophiliaAstraZeneca · NCT06750289 · 130 enrolled · United States, Bulgaria, Canada and more
- Feb 17, 2026Phase 3 study in AsthmaAstraZeneca · NCT07444567 · 230 planned · United States, Argentina, Austria and more
Ahead
- Dec 23, 2026Primary completion: phase 3 study in AsthmaAstraZeneca · NCT05692180
- Feb 20, 2028Primary completion: phase 3 study in Churg-Strauss SyndromeAstraZeneca · NCT06512883
- Dec 27, 2029Primary completion: phase 3 study in AsthmaAstraZeneca · NCT07444567
TargetBeta
“Interleukin-5 receptor subunit alpha inhibitor”ChEMBL 37, by rule
Studies
All 48 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07444567Asthma · United States, Argentina, Austria and more | 3 | Recruiting | AstraZeneca | Dec 27, 2029 | 230 |
| NCT06750289Pulmonary Eosinophilia · United States, Bulgaria, Canada and more | 3 | Completed | AstraZeneca | Sep 21, 2026 | 130 |
| NCT06512883Churg-Strauss Syndrome · United States, Brazil, Canada and more | 3 | Recruiting | AstraZeneca | Feb 20, 2028 | 14 |
| NCT06465485Pulmonary Eosinophilia · China | 3 | Completed | AstraZeneca | May 13, 2026 | 504 |
| NCT05692180Asthma · United States, Argentina, France and more | 3 | Active, not recruiting | AstraZeneca | Dec 23, 2026 | 94 |
| NCT05552508Asthma · United States, Australia, Belgium and more | 4 | Completed | AstraZeneca | Jul 19, 2024 | 45 |
| NCT05384938In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India · India | 4 | Completed | AstraZeneca | Jul 1, 2023 | 139 |
| NCT05251909Eosinophilic enteropathy · United States, Brazil, Italy and more | 3 | Terminated | AstraZeneca | Feb 13, 2024 | 12 |
| NCT05006573Non-cystic Fibrosis Bronchiectasis · United States, Argentina, Australia and more | 3 | Terminated | AstraZeneca | Apr 16, 2024 | 100 |
| NCT04612790Pemphigoid, Bullous · United States, Australia, Bulgaria and more | 3 | Terminated | AstraZeneca | Oct 26, 2023 | 67 |
| NCT04612725Chronic Urticaria · United States, Bulgaria, Germany and more | 2 | Terminated | AstraZeneca | Oct 13, 2022 | 159 |
| NCT04605094Dermatitis, Atopic · United States, Australia, Bulgaria and more | 2 | Terminated | AstraZeneca | Apr 25, 2022 | 194 |
| NCT04543409Eosinophilic Esophagitis · United States, Canada, France and more | 3 | Terminated | AstraZeneca | Sep 19, 2022 | 211 |
| NCT04191304Hypereosinophilic Syndrome · United States, Argentina, Austria and more | 3 | Active, not recruiting | AstraZeneca | May 7, 2025 | 134 |
| NCT04305405Asthma · United States, Japan | 3 | Completed | AstraZeneca | Sep 12, 2022 | 30 |
| NCT04157335Nasal Polyps · United States, Argentina, Australia and more | 3 | Terminated | AstraZeneca | Aug 6, 2024 | 295 |
| NCT04159519Asthma · France, Germany, Italy and more | 4 | Completed | AstraZeneca | Jan 31, 2023 | 170 |
| NCT04157348Churg-Strauss Syndrome · United States, Belgium, Canada and more | 3 | Active, not recruiting | AstraZeneca | Aug 10, 2023 | 140 |
| NCT04053634Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Jul 28, 2025 | 689 |
| NCT03953300Asthma · United States, Canada, Denmark and more | 4 | Completed | AstraZeneca | Oct 20, 2026 | 75 |
| NCT03928262Healthy Subjects · Hong Kong | 1 | Completed | AstraZeneca | Aug 12, 2019 | 36 |
| NCT03557307Asthma · United States, Argentina, Belgium and more | 3 | Completed | AstraZeneca | Apr 16, 2021 | 598 |
| NCT03401229Nasal Polyps · United States, Austria, Belgium and more | 3 | Completed | AstraZeneca | Jul 31, 2020 | 413 |
| NCT03170271Asthma · United States, Austria, Belgium and more | 3 | Completed | AstraZeneca | Sep 25, 2019 | 660 |
| NCT03186209Asthma · China, Korea, Republic of, Philippines and more | 3 | Completed | AstraZeneca | Jan 30, 2023 | 695 |
| NCT02968914Asthma · Germany | 1 | Completed | AstraZeneca | Jul 13, 2017 | 180 |
| NCT02918071Asthma · United States, Canada | 3 | Completed | AstraZeneca | Aug 21, 2017 | 121 |
| NCT02869438Asthma · United States, Chile, Germany and more | 3 | Completed | AstraZeneca | Aug 1, 2018 | 233 |
| NCT02821416Asthma · Canada | 3 | Completed | AstraZeneca | Oct 22, 2019 | 46 |
| NCT02814643Asthma · United States | 3 | Completed | AstraZeneca | Jan 24, 2017 | 103 |
| NCT02808819Asthma · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Jun 18, 2020 | 447 |
| NCT02772419Eosinophilic Chronic Rhinosinusitis · Japan | 2 | Completed | Kyowa Kirin | Mar 27, 2017 | 63 |
| NCT02417961Asthma · United States, Canada | 3 | Completed | AstraZeneca | Mar 14, 2016 | 162 |
| NCT02322775Asthma · United States, Canada, Germany and more | 3 | Completed | AstraZeneca | Oct 7, 2015 | 211 |
| NCT02258542Asthma · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Oct 18, 2017 | 2,133 |
| NCT02155660Lung Diseases, Obstructive · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Apr 9, 2018 | 2,255 |
| NCT02138916Lung Diseases, Obstructive · United States, Austria, Canada and more | 3 | Completed | AstraZeneca | Apr 10, 2018 | 1,656 |
| NCT02075255Asthma · United States, Argentina, Bulgaria and more | 3 | Completed | AstraZeneca | Aug 8, 2016 | 220 |
| NCT01947946Asthma · United States, Argentina, Brazil and more | 3 | Terminated | AstraZeneca | Jul 2014 | 13 |
| NCT01928771Asthma · United States, Australia, Brazil and more | 3 | Completed | AstraZeneca | Apr 5, 2016 | 2,681 |
| NCT01914757Asthma · United States, Argentina, Canada and more | 3 | Completed | AstraZeneca | Mar 2016 | 2,508 |
| NCT01412736Uncontrolled and Suspected Eosinophilic Asthma · Japan, Korea, Republic of | 2 | Completed | Kyowa Kirin | Jul 2013 | 106 |
| NCT01238861Asthma · United States, Argentina, Brazil and more | 2 | Completed | AstraZeneca | Mar 2013 | 964 |
| NCT01227278Pulmonary Disease, Chronic Obstructive · United States, Canada, Denmark and more | 2 | Completed | AstraZeneca | Jan 2013 | 421 |
| NCT00783289Asthma · United States | 2 | Completed | AstraZeneca | Nov 17, 2009 | 35 |
| NCT00768079Asthma · United States, Canada | 2 | Completed | AstraZeneca | Dec 17, 2010 | 110 |
| NCT00659659Asthma · United States, Canada | 1 | Completed | AstraZeneca | Jan 2011 | 27 |
| NCT00512486Asthma · United States | 1 | Completed | AstraZeneca | Sep 2008 | 42 |
How it is read
Names in the registry
- “Benralizumab”, 38 entries
- “benralizumab”, 3 entries
- “Benralizumab 100 mg”, 3 entries
- “KHK4563”, 3 entries
- “MEDI-563”, 3 entries
Conditions, from the studies’ own filings
- Asthma, 29 studies
- Pulmonary Disease, Chronic Obstructive, 4 studies
- Churg-Strauss Syndrome, 2 studies
- Nasal Polyps, 2 studies
- Hypereosinophilic Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.